Table 2 Efficacy Outcomes
A. Percentage change from baseline for medicine parameters expressed in median (interquartile range) | ||||
|---|---|---|---|---|
Outcome | Phases | Intervention (N = 126) | Control (N = 127) | p value |
Total Daily Dose (TDD) | Inpatient phase, day 14 postrecruitment | ̶ -12.50 (−27.27, 0.00) | 0.00 (−11.43, 6.67) | < 0.001 |
Inpatient phase, day 28 postrecruitment | −14.91 (−32.00, 0.00) | 0.00 (− 11.76, 7.14) | < 0.001 | |
Discharge day (Primary Outcome) | − 19.62 (− 34.38, 0.00) | 0.00 (− 12.00, 6.82) | < 0.001 | |
Outpatient phase, day 28 postdischarge | − 22.54 (− 41.18, 0.00) | ̶7.69 (− 28.57, 0.00) | 0.001 | |
Total Number of Medicine (TNM) | Inpatient phase, day 14 postrecruitment | ̶ 5.26 (− 16.67, 0.00) | 0.00 (−9.09, 5.88) | 0.008 |
Inpatient phase, day 28 postrecruitment | 0.00 (− 18.18, 5.56) | 0.00 (−10.00, 5.88) | 0.035 | |
Discharge day | ̶ 5.56 (−20.00, 0.00) | 0.00 (−11.76, 5.88) | 0.035 | |
Outpatient phase, day 28 postdischarge | ̶ 7.14 (−23.08, 0.00) | 0.00(−16.67, 5.56) | 0.203 | |
Total Daily Cost (TDC) | Inpatient phase, day 14 postrecruitment | ̶ 8.91 (−27.55, 0.00) | 0.00 (−14.99, 3.57) | 0.004 |
Inpatient phase, day 28 postrecruitment | −10.66 (−35.86, 0.00) | 0.00 (−15.83, 5.63) | 0.002 | |
Discharge day | −14.74 (−38.22, 0.00) | 0.00 (−23.90, 7.60) | 0.001 | |
Outpatient phase, day 28 postdischarge | −17.31 (−47.07, 0.00) | ̶ 7.61 (−37.63, 1.80) | 0.116 | |
B: Analysis of the change of TDC/TNM/TDC across time using GLMM | ||||
Regression Coefficient (95% CI) | p value | |||
TDD | Unadjusted group effects | −2.836 (−4.888, −0.785) | 0.007 | |
Adjusted* group effects | −3.113 (−5.153, −1.072) | 0.003 | ||
TNM | Unadjusted group effects | −0.830 (−1.875, 0.216) | 0.120 | |
Adjusted group effects | −0.994 (−2.046, 0.0587) | 0.064 | ||
TDC | Unadjusted group effects | −3.564 (−10.882, 3.754) | 0.340 | |
Adjusted group effects | −3.585 (−10.830, 3.661) | 0.332 | ||